article thumbnail

Day Zero Antivirals for Future Pandemics

Codon

Remdesivir and other broad-spectrum antivirals work by jamming up RNA-dependent RNA polymerase (RdRp), an enzyme that nearly all RNA viruses use to replicate their genomes. Other efforts to build broad-spectrum antivirals have focused on another conserved feature of viruses: double-stranded RNA.

RNA 87
article thumbnail

Oditrasertib,

New Drug Approvals

2-NTP , an analog of ATP, inhibits the SARS-CoV-2 RNA-dependent RNA polymerase replication and transcription of viral RNA. 2012). “Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides” Bioorganic & Medicinal Chemistry Letters. Saunders, O.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Marvin Caruthers receives inaugural Merkin Prize in ceremony at the Broad Institute for DNA synthesis technology

Broad Institute

Today, scientists use such reactions to produce the customizable DNA and RNA molecules that enable genetic sequencing, drug and vaccine development, pathogen tests, cancer diagnostics, and more. It is because we had the Fellowship that we could buy our very first DNA and RNA synthesizer in the lab.”

DNA 52
article thumbnail

Leveraging ADCs in precision oncology strategy

Drug Target Review

By identifying proteins that only interact with each other in cancer, but not normal tissues, we can really expand the repertoire of ADC therapeutics beyond monoclonal antibodies developed based solely on RNA expression profiles. His work has been published in many high-impact journals and presented at international oncology meetings.

article thumbnail

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

The Pharma Data

The study showed the antiviral activity of GSK’254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. Shionogi joined in October 2012. At the conclusion of the study, the largest mean changes in viral load were -1.5 log 10 and -2.0

article thumbnail

Clinical Catch-Up: January 4-8 | BioSpace

The Pharma Data

Precigen received the okay from the FDA to initiate a Phase I trial of PRGN-2012 in recurrent respiratory papillomatosis (RRP). PRGN-2012 is a first-in-class, off-the-shelf AdenoVerse immunotherapy using the company’s gorilla adenovector technology, part of its proprietary AdenoVerse platform.

article thumbnail

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Drug Target Review

Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. 2012 Feb 1;24(1):107-15. in North America) in late 2017. Biophysical Journal.